MAXONA PHARMACEUTICALS
Maxona is a pharmaceutical company that develops and commercializes a portfolio of novel therapeutics for the treatment of pain. It is developing MAX-001 as the first novel therapeutic alternative to opioids and NSAIDs for the treatment of pain. While the U.S. is currently experiencing an opioid abuse epidemic, there has been very limited innovation to address the needs of millions of Americans suffering from acute and chronic pain. Hence, there is a significant need for safe and efficacious alternative analgesics. MAX-001 is an ex-US marketed non-opioid, non-NSAID analgesic New Molecular Entity that aims to fundamentally address the shortcomings of existing therapies. The company was founded in 2015 and is based in King of Prussia, Pennsylvania.
MAXONA PHARMACEUTICALS
Social Links:
Industry:
Biotechnology Health Care Life Science Pharmaceutical Therapeutics
Founded:
2015-01-01
Address:
King Of Prussia, Pennsylvania, United States
Country:
United States
Website Url:
http://www.maxonapharm.com
Total Employee:
1+
Status:
Active
Contact:
(484) 684 - 7737
Email Addresses:
[email protected]
Total Funding:
5.56 M USD
Technology used in webpage:
SPF LetsEncrypt Microsoft Exchange Online Office 365 Mail Google Maps Google Maps API Gravatar Profiles Unified Layer ReCAPTCHA V3 HostGator
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focusesย on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Menten AI
Menten AI develops peptide and protein therapeutics using machine learning and quantum computing.
Current Employees Featured
Founder
Official Site Inspections
http://www.maxonapharm.com
- Host name: 198.49.23.144
- IP address: 198.49.23.144
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013

More informations about "Maxona Pharmaceuticals"
Leadership โ Maxona Pharmaceuticals
MAXONA Pharmaceuticals expert leadership team is focused on delivering against the companyโs commitment to leveraging innovation to address patientโs unmet medical needs.See details»
Maxona Pharmaceuticals
MAXONAโs lead compound, MAX-001 is initially being developed in the U.S. to treat acute and chronic pain. MAX-001 is an optimized formulation of an active molecule which is a non โฆSee details»
MAXONA Pharmaceuticals, Inc. - Crunchbase Company Profile
Organization. MAXONA Pharmaceuticals, Inc. Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email โฆSee details»
Maxona Pharmaceuticals - Org Chart, Teams, Culture & Jobs - The โฆ
View Maxona Pharmaceuticals' up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
MAXONA Pharmaceuticals: Contact Details and Business Profile
MAXONA Pharmaceuticals, Inc. is a privately held, clinical stage, specialty pharmaceutical company focused on the development and commercialization of a portfolio of novel โฆSee details»
Investors โ Maxona Pharmaceuticals
Richard Brand, Chief Financial Officer. MAXONA Pharmaceuticals. [email protected]. 201-577-8221See details»
MAXONA Pharmaceuticals - LinkedIn
MAXONA Pharmaceuticals, Inc. is a privately held, clinical stage, specialty pharmaceutical company focused on the development and commercialization of a portfolio of novel โฆSee details»
Leadership Team - The Org
The leadership team at Maxona Pharmaceuticals has a history of experience in the finance and accounting industries, as well as healthcare and marketing.See details»
MAXONA Pharmaceuticals, Inc. - Contacts, Employees, Board โฆ
MAXONA is a pharmaceutical company that develops and commercializes a portfolio of novel therapeutics for the treatment of pain.See details»
MAXONA Pharmaceuticals - Overview, Revenue, Employee
MAXONA Pharmaceuticals, Inc. is a privately held, clinical stage, specialty pharmaceutical company focused on the development and commercialization of a portfolio of novel โฆSee details»
MAXONA Pharmaceuticals, LLC - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for MAXONA Pharmaceuticals, LLC of Malvern, PA. Get the latest business insights from Dun & Bradstreet.See details»
MAXONA Pharmaceuticals, LLC. - VentureRadar
Website: http://www.maxonapharm.com. Offers alternative pain treatments to NSAIDs and opioid analgesics through novel therapeutics, leveraging extensive safety and ...See details»
News & Contact - Maxona Pharmaceuticals
Feb 11, 2025 MAXONA Pharmaceuticals, Inc. 101 Lindenwood Drive, Suite 225 Malvern, PA 19355. Tel: (484) 684 โ 7737 Fax: (484) 681 โ 5626. [email protected]See details»
MAXONA Pharmaceuticals - Products, Competitors, Financials, โฆ
Maxonapharm.com. Overview & Products; Financials; People; Stage Unattributed | Alive. Total Raised $5.56M. Last Raised $5.56M | 4 yrs ago. About MAXONA Pharmaceuticals. MAXONA โฆSee details»
MAXONA Pharmaceuticals - Company Profile & Staff Directory
MAXONA Pharmaceuticals, Inc. is a privately held, clinical stage, specialty pharmaceutical company focused on the development and commercialization of a portfolio of novel โฆSee details»
Maxona Pharmaceuticals - PitchBook
Maxona Pharmaceuticals General Information Description. Operator of a pharmaceutical company intended to develop novel therapeutics for the treatment of moderate to severe pain โฆSee details»
MAXONA Pharmaceuticals - Overview, News & Similar companies
MAXONA Pharmaceuticals contact info: Phone number: (484) 684-7737 Website: www.maxonapharm.com What does MAXONA Pharmaceuticals do? MAXONA โฆSee details»
MAXONA Pharmaceuticals | Life Sciences PA
Www.maxonapharm.com; About. MAXONA Pharmaceuticals, LLC. is a privately held, clinical stage, specialty pharmaceutical company focused on the development and commercialization โฆSee details»
MAXONA Pharmaceuticals | Biotech Careers
MAXONA Pharmaceuticals Inc., is developing a novel non-opioid, non-NSAID, non-CBD analgesic as a New Molecular Entity for the treatment of pain in the United States Business โฆSee details»
Simplification for success: Rewiring the biopharma operating model
Mar 21, 2025 Thirty-seven of them expect their organization to pursue a simplification effort over the next 12 months. Thirty-two respondents say they believe they need a significantly different โฆSee details»